添加
<img src="https://imageproxy.pbkrs.com/https://cdn.rttnews.com/images/v4/RTTNews-Logo-224x61.png?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://cdn.rttnews.com/images/v4/RTTNews-Logo-224x61.png"/>
作為您在 Google 上的首選新聞來源
<img src="https://imageproxy.pbkrs.com/https://cdn.rttnews.com/images/v4/google.png?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://cdn.rttnews.com/images/v4/google.png"/>
立即添加
多個醫療保健和生物技術公司在週五的盤後交易中出現顯著漲幅，動力來自臨牀更新、近期公告和技術反彈。
Kymera Therapeutics Inc. (KYMR) 在盤後交易中飆升至 73.00 美元，較收盤上漲 9.58%。該股在常規交易時段以 66.62 美元收盤，微幅上漲 0.59%。該公司準備在 12 月 8 日（週一）公佈其口服 STAT6 降解劑 KT-621 在中重度特應性皮炎的 BroADen 1b 期臨牀試驗的結果。對這一結果的期待似乎推動了強勁的盤後動能。
Ocular Therapeutix Inc. (OCUL) 的股價在盤後上漲至 14.00 美元，漲幅為 11.29%。該股在白天以 12.58 美元收盤，上漲 1.21%。雖然週五沒有發佈新的更新，但該公司最近宣佈在非增殖性糖尿病視網膜病變的 AXPAXLI (OTX-TKI) 的 HELIOS-3 3 期註冊項目中取得進展，第一位患者於 11 月 24 日被隨機分配。
Guardian Pharmacy Services Inc. (GRDN) 的股價在盤後交易中上漲至 30.54 美元，漲幅為 2.62%。該股在白天以 29.76 美元收盤，上漲 1.50%。該公司週五沒有發佈新的更新，但該股在晚間交易中延續了上漲趨勢。
Predictive Oncology Inc. (POAI) 的股價在盤後上漲至 4.84 美元，漲幅為 13.62%，此前在常規交易中大幅下跌，股價跌至 4.26 美元，跌幅超過 22%。本週早些時候，該公司披露已重新符合納斯達克的最低股東權益要求，確保在納斯達克資本市場的持續上市。盤後交易的反彈表明在合規更新後信心恢復。
Acumen Pharmaceuticals Inc. (ABOS) 的股價在盤後小幅上漲至 1.92 美元，漲幅為 3.23%。該股在白天以 1.86 美元收盤，下跌 6.06%。該公司最近在阿爾茨海默病臨牀試驗會議（CTAD）上展示了新研究，強調通過轉鐵蛋白受體通路改善 AßO 靶向抗體的遞送。與 JCR Pharmaceuticals 的合作工作正在向臨牀測試推進，支持長期發展前景。
EUDA Health Holdings Ltd. (EUDA) 的股價在盤後上漲至 2.93 美元，漲幅為 7.72%。該股在白天以 2.72 美元收盤，下跌 6.85%。在 11 月 26 日，該公司宣佈與 Streeterville Capital 達成一項價值 100,000 美元的可轉換認股權證的證券購買協議，最多可行使 2 百萬股，行使價為每股 6.00 美元。該協議為 EUDA 追求增長計劃提供了額外的融資靈活性。
Butterfly Network Inc. (BFLY) 的股價在盤後上漲至 3.21 美元，漲幅為 4.90%。該股在常規交易時段以 3.06 美元平盤收盤。週五沒有發佈新的公告，但該股的走勢反映了盤後交易中的活躍情況。
如有意見和反饋，請聯繫：editorial@rttnews.com
商業新聞

KYMR

OCUL

POAI

AGPU

幾隻醫療保健和生物技術股票，包括 Kymera Therapeutics、Ocular Therapeutix 和 Predictive Oncology，在週五的盤後交易中均出現顯著上漲。這一勢頭受到臨牀更新、近期公告和技術反彈的推動。Kymera 因對臨牀試驗結果的預期上漲了 9.58%，而 Predictive Oncology 在重新獲得納斯達克合規後反彈了 13.62%

Add
<div class="lb-trans">添加
</div><img src="https://imageproxy.pbkrs.com/https://cdn.rttnews.com/images/v4/RTTNews-Logo-224x61.png" alt="" original-src="https://cdn.rttnews.com/images/v4/RTTNews-Logo-224x61.png"/>
as your preferred news source on Google
<div class="lb-trans">作為您在 Google 上的首選新聞來源
</div><img src="https://imageproxy.pbkrs.com/https://cdn.rttnews.com/images/v4/google.png" alt="" original-src="https://cdn.rttnews.com/images/v4/google.png"/>
Add Now
<div class="lb-trans">立即添加
</div>Several healthcare and biotech names posted notable gains in Friday's after-hours trading session, with momentum driven by clinical updates, recent announcements, and technical rebounds.
<div class="lb-trans">多個醫療保健和生物技術公司在週五的盤後交易中出現顯著漲幅，動力來自臨牀更新、近期公告和技術反彈。
</div>Kymera Therapeutics Inc. (KYMR) surged in extended trading, climbing to $73.00, a 9.58% rise from the close. Shares had ended the regular session at $66.62, up modestly by 0.59%. The company is preparing to announce results from the BroADen Phase 1b clinical trial of KT-621, its oral STAT6 degrader for moderate to severe atopic dermatitis, on Monday, December 8. Anticipation around this readout appears to have fueled strong after-hours momentum.
<div class="lb-trans">Kymera Therapeutics Inc. (KYMR) 在盤後交易中飆升至 73.00 美元，較收盤上漲 9.58%。該股在常規交易時段以 66.62 美元收盤，微幅上漲 0.59%。該公司準備在 12 月 8 日（週一）公佈其口服 STAT6 降解劑 KT-621 在中重度特應性皮炎的 BroADen 1b 期臨牀試驗的結果。對這一結果的期待似乎推動了強勁的盤後動能。
</div>Shares of Ocular Therapeutix Inc. (OCUL) advanced to $14.00 after hours, marking an 11.29% increase. The stock closed at $12.58, up 1.21% during the day. While no fresh updates were released on Friday, the company recently announced progress in its HELIOS-3 Phase 3 registrational program for AXPAXLI (OTX-TKI) in non-proliferative diabetic retinopathy, with the first patient randomized on November 24.
<div class="lb-trans">Ocular Therapeutix Inc. (OCUL) 的股價在盤後上漲至 14.00 美元，漲幅為 11.29%。該股在白天以 12.58 美元收盤，上漲 1.21%。雖然週五沒有發佈新的更新，但該公司最近宣佈在非增殖性糖尿病視網膜病變的 AXPAXLI (OTX-TKI) 的 HELIOS-3 3 期註冊項目中取得進展，第一位患者於 11 月 24 日被隨機分配。
</div>Guardian Pharmacy Services Inc. (GRDN) shares rose to $30.54 in after-hours trading, a 2.62% gain. Shares had closed at $29.76, up 1.50% earlier in the day. The company did not issue new updates on Friday, but the stock extended its upward trajectory into the evening session.
<div class="lb-trans">Guardian Pharmacy Services Inc. (GRDN) 的股價在盤後交易中上漲至 30.54 美元，漲幅為 2.62%。該股在白天以 29.76 美元收盤，上漲 1.50%。該公司週五沒有發佈新的更新，但該股在晚間交易中延續了上漲趨勢。
</div>Predictive Oncology Inc. (POAI) jumped to $4.84 after hours, a 13.62% rise, following a sharp decline during the regular session, where shares fell more than 22% to $4.26. Earlier in the week, the company disclosed that it had regained compliance with Nasdaq's minimum stockholders' equity requirement, ensuring continued listing on the Nasdaq Capital Market. The rebound in extended trading suggests renewed confidence after the compliance update.
<div class="lb-trans">Predictive Oncology Inc. (POAI) 的股價在盤後上漲至 4.84 美元，漲幅為 13.62%，此前在常規交易中大幅下跌，股價跌至 4.26 美元，跌幅超過 22%。本週早些時候，該公司披露已重新符合納斯達克的最低股東權益要求，確保在納斯達克資本市場的持續上市。盤後交易的反彈表明在合規更新後信心恢復。
</div>Shares of Acumen Pharmaceuticals Inc. (ABOS) edged higher to $1.92 after hours, up 3.23%. Shares had closed at $1.86, down 6.06% during the day. The company recently presented new research at the Clinical Trials on Alzheimer's Disease (CTAD) conference, highlighting improved delivery of AßO-targeting antibodies through the transferrin receptor pathway. Collaborative work with JCR Pharmaceuticals is now advancing toward clinical testing, supporting long-term development prospects.
<div class="lb-trans">Acumen Pharmaceuticals Inc. (ABOS) 的股價在盤後小幅上漲至 1.92 美元，漲幅為 3.23%。該股在白天以 1.86 美元收盤，下跌 6.06%。該公司最近在阿爾茨海默病臨牀試驗會議（CTAD）上展示了新研究，強調通過轉鐵蛋白受體通路改善 AßO 靶向抗體的遞送。與 JCR Pharmaceuticals 的合作工作正在向臨牀測試推進，支持長期發展前景。
</div>EUDA Health Holdings Ltd. (EUDA) rose to $2.93 after hours, a 7.72% gain. The stock had closed at $2.72, down 6.85% earlier in the day. On November 26, the company announced a securities purchase agreement with Streeterville Capital for a convertible warrant valued at $100,000, exercisable for up to 2 million shares at $6.00 per share. The agreement provides additional financing flexibility as EUDA pursues growth initiatives.
<div class="lb-trans">EUDA Health Holdings Ltd. (EUDA) 的股價在盤後上漲至 2.93 美元，漲幅為 7.72%。該股在白天以 2.72 美元收盤，下跌 6.85%。在 11 月 26 日，該公司宣佈與 Streeterville Capital 達成一項價值 100,000 美元的可轉換認股權證的證券購買協議，最多可行使 2 百萬股，行使價為每股 6.00 美元。該協議為 EUDA 追求增長計劃提供了額外的融資靈活性。
</div>Butterfly Network Inc. (BFLY) gained to $3.21 after hours, up 4.90%. Shares had finished the regular session flat at $3.06. No new announcements were made on Friday, but the stock's move reflects renewed activity in extended trading.
<div class="lb-trans">Butterfly Network Inc. (BFLY) 的股價在盤後上漲至 3.21 美元，漲幅為 4.90%。該股在常規交易時段以 3.06 美元平盤收盤。週五沒有發佈新的公告，但該股的走勢反映了盤後交易中的活躍情況。
</div>For comments and feedback contact: editorial@rttnews.com
<div class="lb-trans">如有意見和反饋，請聯繫：editorial@rttnews.com
</div>Business News
<div class="lb-trans">商業新聞
</div>

醫療保健公司在盤後交易中表現強勁：Kymera Therapeutics、Ocular Therap、Predictive Oncology 位列漲幅榜前列